Isolation and characterization of anti-inflammatory and anti-proliferative compound, for B-cell Non-Hodgkin lymphoma, from Nyctanthes arbor-tristis Linn.
Anti-tumoral effect of arsenic compound, sodium metaarsenite (KML001), in non-Hodgkin's lymphoma: an in vitro and in vivo study.
ZCL-082, a boron-containing compound, induces apoptosis of non-Hodgkin's lymphoma via targeting p90 ribosomal S6 kinase 1/NF-κB signaling pathway.
Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: A comprehensive review.
Yasuda H, Yasuda M, Komatsu N.
Cancer Sci. 2021 Jul;112(7):2607-2624. doi: 10.1111/cas.14933. Epub 2021 Jun 11.
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, Coindre JM, Blakemore SJ, Clawson A, Suttle B, McDonald AA, Woodruff M, Ribich S, Hedrick E, Keilhack H, Thomson B, Owa T, Copeland RA, Ho PTC, Ribrag V.
Lancet Oncol. 2018 May;19(5):649-659. doi: 10.1016/S1470-2045(18)30145-1. Epub 2018 Apr 9.
Nuclear Export in Non-Hodgkin Lymphoma and Implications for Targeted XPO1 Inhibitors.
Trkulja KL, Manji F, Kuruvilla J, Laister RC.
Biomolecules. 2023 Jan 5;13(1):111. doi: 10.3390/biom13010111.
The association between non-Hodgkin lymphoma and organophosphate pesticides exposure: A meta-analysis.
Hu L, Luo D, Zhou T, Tao Y, Feng J, Mei S.
Environ Pollut. 2017 Dec;231(Pt 1):319-328. doi: 10.1016/j.envpol.2017.08.028. Epub 2017 Aug 12.
Isolation and characterization of anti-inflammatory and anti-proliferative compound, for B-cell Non-Hodgkin lymphoma, from Nyctanthes arbor-tristis Linn.
Sana T, Qayyum S, Jabeen A, Siddiqui BS, Begum S, Siddiqui RA, Hadda TB.
J Ethnopharmacol. 2022 Jul 15;293:115267. doi: 10.1016/j.jep.2022.115267. Epub 2022 Apr 7.
PI3Kdelta-selective and PI3Kalpha/delta-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
Lampson BL, Brown JR.
Expert Opin Investig Drugs. 2017 Nov;26(11):1267-1279. doi: 10.1080/13543784.2017.1384815. Epub 2017 Oct 6.
Radioimmunotherapy for non-Hodgkin's lymphoma.
Emmanouilides C.
Semin Oncol. 2003 Aug;30(4):531-44. doi: 10.1016/s0093-7754(03)00237-9.
Venetoclax active and safe in non-Hodgkin lymphoma.
Das M.
Lancet Oncol. 2017 Mar;18(3):e136. doi: 10.1016/S1470-2045(17)30063-3. Epub 2017 Jan 28.
Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Ng SY, Davids MS.
Clin Adv Hematol Oncol. 2014 Apr;12(4):224-9.
Prediction of Stem Cell Mobilization Failure in Patients with Hodgkin and Non-Hodgkin Lymphoma.
Demiroğlu H, Çiftçiler R, Büyükaşık Y, Göker H.
Turk J Haematol. 2021 Aug 25;38(3):204-210. doi: 10.4274/tjh.galenos.2020.2020.0409. Epub 2020 Nov 9.
